"We believe there is a
$54.4 billion saving opportunity between 2017 and 2022 if [a dozen] biosimilars
come to market when the originator patents expire."
— Jennifer Luddy, a spokesperson for Express Scripts, talked
with AIS's RADAR on Drug
Benefits about the 2019 drug pipeline, as several blockbuster
drugs, including EpiPen and Lyrica, will come off patent protection this year.
No comments:
Post a Comment